Martingale Asset Management’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Martingale Asset Management’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,503	Closed	-$593K	–	956
2020 Q4	$593K	Sell	4,503 -27,602	-86%	-$2.44M	0.01%	577
2020 Q3	$1.62M	Sell	32,105 -20,600	-39%	-$926K	0.02%	484
2020 Q2	$2.51M	Buy	+52,705	New	+$2.45M	0.03%	460

Martingale Asset Management's EIDX Position: Q1 2021 in Review

Martingale Asset Management sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 4,503 shares — an estimated $593K sold.

Martingale Asset Management first reported a position in EIDX in Q2 2020 and held it in 3 quarters. The position peaked at $2.51M in Q2 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Martingale Asset Management reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Martingale Asset Management sold 4,503 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $593K.
Martingale Asset Management first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
Martingale Asset Management's Eidos Therapeutics, Inc. Common Stock position peaked at $2.51M in Q2 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Martingale Asset Management's 13F filing for Q1 2021, filed 13 May 2021.